- Home
- PHGE vs BIAF Comparison
PHGE vs BIAF Comparison
Compare PHGE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- BIAF
- Stock Information
- Founded
- PHGE 2015
- BIAF 2014
- Country
- PHGE Israel
- BIAF United States
- Employees
- PHGE N/A
- BIAF N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PHGE Health Care
- BIAF Health Care
- Exchange
- PHGE Nasdaq
- BIAF Nasdaq
- Market Cap
- PHGE 26.5M
- BIAF 21.4M
- IPO Year
- PHGE N/A
- BIAF 2022
- Fundamental
- Price
- PHGE $0.49
- BIAF $1.24
- Analyst Decision
- PHGE Strong Buy
- BIAF Strong Buy
- Analyst Count
- PHGE 2
- BIAF 1
- Target Price
- PHGE $22.50
- BIAF $6.00
- AVG Volume (30 Days)
- PHGE 159.9K
- BIAF 102.5K
- Earning Date
- PHGE 11-14-2024
- BIAF 11-14-2024
- Dividend Yield
- PHGE N/A
- BIAF N/A
- EPS Growth
- PHGE N/A
- BIAF N/A
- EPS
- PHGE N/A
- BIAF N/A
- Revenue
- PHGE N/A
- BIAF $9,367,785.00
- Revenue This Year
- PHGE N/A
- BIAF $302.41
- Revenue Next Year
- PHGE N/A
- BIAF $15.00
- P/E Ratio
- PHGE N/A
- BIAF N/A
- Revenue Growth
- PHGE N/A
- BIAF 2813.87
- 52 Week Low
- PHGE $0.49
- BIAF $1.20
- 52 Week High
- PHGE $8.55
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- PHGE 21.78
- BIAF 36.67
- Support Level
- PHGE $0.56
- BIAF $1.21
- Resistance Level
- PHGE $0.79
- BIAF $1.37
- Average True Range (ATR)
- PHGE 0.10
- BIAF 0.08
- MACD
- PHGE -0.02
- BIAF 0.01
- Stochastic Oscillator
- PHGE 0.00
- BIAF 17.50
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.